Obstructive sleep apnea (OSA)
Airway collapse during sleep, linked to obesity. Zepbound gained an OSA indication in 2024.
OSA is repetitive airway collapse during sleep, strongly tied to obesity. Tirzepatide (Zepbound) received an FDA OSA indication for adults with obesity in 2024 based on the SURMOUNT-OSA trial.